S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
NYSE:HQL

Tekla Life Sciences Investors Stock Forecast, Price & News

$17.38
-0.40 (-2.25%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.35
$17.89
50-Day Range
$17.38
$20.60
52-Week Range
$17.35
$22.70
Volume
159,948 shs
Average Volume
140,268 shs
Market Capitalization
$421.97 million
P/E Ratio
N/A
Dividend Yield
9.51%
Beta
0.88
30 days | 90 days | 365 days | Advanced Chart
Receive HQL News and Ratings via Email

Sign-up to receive the latest news and ratings for Tekla Life Sciences Investors and its competitors with MarketBeat's FREE daily newsletter.


Tekla Life Sciences Investors logo

About Tekla Life Sciences Investors

Tekla Life Sciences Investors operates as a closed-end investment fund or Investment trust. The firm engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Investment offices, not elsewhere classified
Sub-Industry
N/A
Sector
Finance
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
21,837,000
Market Cap
$421.97 million
Optionable
Not Optionable

Company Calendar

Ex-Dividend for 12/31 Dividend
11/23/2021
Dividend Payable
12/31/2021
Today
1/21/2022
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

1.41 out of 5 stars

Finance Sector

1024th out of 1,353 stocks

Investment Offices, Not Elsewhere Classified Industry

37th out of 156 stocks

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 1.7Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions

How has Tekla Life Sciences Investors' stock price been impacted by Coronavirus?

Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HQL stock has increased by 17.0% and is now trading at $17.38.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Tekla Life Sciences Investors?

Tekla Life Sciences Investors saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 14,500 shares, a decline of 85.8% from the December 15th total of 102,200 shares. Based on an average trading volume of 72,600 shares, the short-interest ratio is currently 0.2 days.
View Tekla Life Sciences Investors' Short Interest
.

How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors?

Tekla Life Sciences Investors announced a quarterly dividend on Monday, November 15th. Investors of record on Wednesday, November 24th will be given a dividend of $0.42 per share on Friday, December 31st. This represents a $1.68 annualized dividend and a dividend yield of 9.67%. The ex-dividend date is Tuesday, November 23rd.
View Tekla Life Sciences Investors' dividend history
.

Is Tekla Life Sciences Investors a good dividend stock?

Tekla Life Sciences Investors pays an annual dividend of $1.69 per share and currently has a dividend yield of 9.51%. HQL has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
View Tekla Life Sciences Investors' dividend history.

Who are Tekla Life Sciences Investors' key executives?

Tekla Life Sciences Investors' management team includes the following people:
  • Dan Omstead, President, Chief Executive Officer & Trustee
  • Jason C. Akus, Senior Vice President-Research
  • Timothy L. Gasperoni, Senior Vice President-Research
  • Laura F. Woodward, Secretary, Treasurer & Chief Compliance Officer

What other stocks do shareholders of Tekla Life Sciences Investors own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include NVIDIA (NVDA), Energy Transfer (ET), QUALCOMM (QCOM), AT&T (T), Enbridge (ENB), International Business Machines (IBM), Kinder Morgan (KMI), Main Street Capital (MAIN), Pfizer (PFE) and Weyerhaeuser (WY).

What is Tekla Life Sciences Investors' stock symbol?

Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."

Who are Tekla Life Sciences Investors' major shareholders?

Tekla Life Sciences Investors' stock is owned by many different retail and institutional investors. Top institutional shareholders include Atlantic Union Bankshares Corp (0.41%), Parallel Advisors LLC (0.04%) and Future Financial Wealth Managment LLC (0.01%). Company insiders that own Tekla Life Sciences Investors stock include Daniel R Omstead and Daniel R Omstead.
View institutional ownership trends for Tekla Life Sciences Investors
.

Which institutional investors are selling Tekla Life Sciences Investors stock?

HQL stock was sold by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, and Atlantic Union Bankshares Corp.
View insider buying and selling activity for Tekla Life Sciences Investors
or view top insider-selling stocks.

Which institutional investors are buying Tekla Life Sciences Investors stock?

HQL stock was bought by a variety of institutional investors in the last quarter, including Future Financial Wealth Managment LLC.
View insider buying and selling activity for Tekla Life Sciences Investors
or or view top insider-buying stocks.

How do I buy shares of Tekla Life Sciences Investors?

Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tekla Life Sciences Investors' stock price today?

One share of HQL stock can currently be purchased for approximately $17.38.

How much money does Tekla Life Sciences Investors make?

Tekla Life Sciences Investors has a market capitalization of $421.97 million.

What is Tekla Life Sciences Investors' official website?

The official website for Tekla Life Sciences Investors is www.teklacap.com.

Where are Tekla Life Sciences Investors' headquarters?

Tekla Life Sciences Investors is headquartered at 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109.

How can I contact Tekla Life Sciences Investors?

Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at (617) 772-8500, via email at [email protected], or via fax at 617-772-8577.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.